美国辉瑞公司宣布与中国三生制药达成协议,共同开发一款抗癌药物。辉瑞将获得该药在中国以外的独家销售权,总交易额最高达60亿美元。其中,三生制药将先获12.5亿美元预付款,并可能因里程碑再获48亿美元。该药名为SSGJ-707,正进行多项癌症治疗试验,预计年内启动3期临床试验。交易预计于第三季度完成,辉瑞还将投资三生制药1亿美元。消息公布后,三生制药股价上涨32%,而辉瑞股价微涨不足1%。免责声明:...
Source Link美国辉瑞公司宣布与中国三生制药达成协议,共同开发一款抗癌药物。辉瑞将获得该药在中国以外的独家销售权,总交易额最高达60亿美元。其中,三生制药将先获12.5亿美元预付款,并可能因里程碑再获48亿美元。该药名为SSGJ-707,正进行多项癌症治疗试验,预计年内启动3期临床试验。交易预计于第三季度完成,辉瑞还将投资三生制药1亿美元。消息公布后,三生制药股价上涨32%,而辉瑞股价微涨不足1%。免责声明:...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.